FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Sorg Elaine K. 2. Date of Event Requiring Statement (MM/DD/YYYY)
11/9/2020 

3. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV]
(Last)       (First)       (Middle)
1 N. WAUKEGAN ROAD
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Sr. V.P., U.S. Commercial Ops. /
(Street)
NORTH CHICAGO, IL 60064      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.01 par value  17595  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option(Right to buy)   (1) 2/14/2028  Common Stock  7080  $114.36  D   
Option(Right to buy)   (2) 2/20/2029  Common Stock  10384  $79.02  D   
Option(Right to buy)   (3) 2/19/2030  Common Stock  45009  $93.50  D   

Explanation of Responses:
(1)  Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 2,360 shares on 2/15/2019, as to 2,360 shares on 2/15/2020 and becomes exercisable as to 2,360 shares on 2/15/2021.
(2)  Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 5,192 shares on 2/21/2020 and becomes exercisable as to 5,192 shares on 2/21/2021, and as to 5192 shares on 2/21/2022.
(3)  Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable as to 15,003 shares on 02/20/2021, as to 15,003 shares on 2/21/2022, and as to 15,003 shares on 2/21/2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Sorg Elaine K.
1 N. WAUKEGAN ROAD
NORTH CHICAGO, IL 60064


Sr. V.P., U.S. Commercial Ops.

Signatures
Steven L. Scrogham, attorney-in-fact for Elaine K. Sorg 11/19/2020
**Signature of Reporting Person Date
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more AbbVie Charts.